Navigation Links
Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
Date:8/23/2013

Jacksonville, FL and Savannah, GA (PRWEB) August 23, 2013

Morphogenesis Inc., a biotechnology firm that has developed a specialized process that educates the immune system to fight cancer in dogs, cats and horses, announces the start of a field study for its personalized cancer treatment for dogs in partnership with SEVO-Med (Southeastern Veterinary Oncology and Medicine).

Tampa-based Morphogenesis and SEVO-Med, a major southeastern veterinary oncology practice which has clinics in Jacksonville and Savannah, are providing the opportunity to pet owners and veterinarians to enroll dogs with High Grade B Cell Lymphoma who might benefit from this personalized treatment.

The first 20 dogs who qualify for the study will be selected. Veterinarians and dog owners who believe their patient/pet could qualify to participate in the study should immediately contact SEVO-Med at 904-278-3870 or 912-355-5791. Once a dog is accepted into the study, treatments and study tests are provided at no cost to the owner.

The vaccine-based cancer treatments developed by Morphogenesis have been shown to manage 17 types of cancer without any side effects in canine, feline and equine patients.

In the treatment developed by Morphogenesis, the dog’s own lymphoma cells undergo a marking process that helps the animal’s immune system recognize the cells as foreign and kill them.

“We educate the body’s immune system to fight its own tumor cells,” said Pat Lawman, Ph.D., CEO of Morphogenesis. “Our process helps keep the cancer in check so that it doesn't progress, and we all think that’s a win.”

“More and more, you are seeing companion animals present with all types of cancers,” Tracy LaDue, DVM, founder of SEVO-Med, wrote in letters to veterinarians informing them of this treatment option for qualifying dogs. “The study being conducted by Morphogenesis and SEVO-Med will further demonstrate the safety and effectiveness of this cutting edge new technology in the fight against lymphoma.”    

About SEVO-Med

Southeast Veterinary Oncology (SEVO) was founded in the Jacksonville suburb of Orange Park, FL, in October, 2004 by double-board certified veterinary oncologist, Tracy LaDue, DVM. At that time, SEVO was one of the first oncology-specific veterinary specialty practices in the U.S. The practice opened its Savannah, GA, clinic in September of 2011. Today, the practices are led by Dr. LaDue and Jennifer Locke, DVM in Florida, and Andrew Daters, DVM, in Georgia. SEVO-Med’s mission is to understand the unique and special bond shared between you and your pet, to offer compassionate guidance, to deliver excellent state of the art medical care, to provide the utmost in client communication and to collaborate with referring veterinarians to develop the best therapy for your pet. For more information, please visit http://www.petcancercare.com or call 904-278-3870 or 912-355-5791.

About Morphogenesis

Morphogenesis is a privately-held biotechnology company structured to serve the rapidly growing cell therapy, biologics and tissue engineering markets. Morphogenesis has developed a multi-indication cancer therapy which educates the immune system to attack tumor cells throughout the body without damaging other cells or systems. Its subsidiary, Veterinary Oncology Services, Inc., assists veterinary physicians in providing this non-toxic, personalized treatment for many types of cancers in cats, dogs and horses. For more information, please visit http://www.veterinaryoncologyservices.com or 813-877-7896 http://www.morphogenesis-inc.com or call 813-875-6600.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11054809.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
2. The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris
3. NYSCF scientists create personalized bone substitutes from skin cells
4. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
5. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
6. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
7. Transplanted brain cells in monkeys light up personalized therapy
8. Research and Markets: Personalized Medicine - Scientific and Commercial Aspects - 2013 Report
9. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
10. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
11. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):